Nagi Bioscience enters the laboratory equipment market

Founded in 2019, Nagi Bioscience is a biotech start-up specialising in developing innovative alternatives to animal testing. Under the premise of unlocking the whole potential of micro-organisms as biological models for any lab, the company developed SydLab One which combines Nagi Bioscience’s patented Organism-on-Chip microfluidic technology with cutting-edge robotics, machine learning, and biology to automate the entire process of culture, treatment, imaging, and multi-phenotypic analysis of small organisms within a single benchtop laboratory device.

SydLab One is the first all-in-one laboratory platform capable of performing end-to-end bioassays and high-content screening of drugs and chemicals on micro-organisms in a fully automated and standardized way. This does not only provide unprecedented data reproducibility and throughput, but also enables the generation of novel datapoints and assays. With the commercialization of SydLab One these possibilities can be now finally offered to any group striving to gain a deep understanding of the efficacy and/or toxicity effects of their drug candidates or chemicals, to boost their discovery programs and prevent late-stage pipeline failures.

Having validated the technology since the foundation of the company with several collaborators and customers across multiple segments, Nagi Bioscience finally enters the laboratory equipment market. As Nagi Bioscience’s CEO and co-founder Matteo Cornaglia, PhD, affirms: “To date, Nagi has been developing its technology and innovative bioassays hand-in-hand with its customers, which put us now in an ideal position to launch a product that truly empowers its users and provides them with a solution tailored to their needs. We are truly proud to introduce to the market SydLab One, and strongly believe in its potential to revolutionize the current standards for small-organism-based testing. This is the result of several years of great teamwork at Nagi and, as a team, we are so excited to hit such an amazing milestone today and ready for this awaited market entry.”

 “Nagi Bioscience could proof with many successful industry collaborations that the SydLab One platform leads to significant time and cost savings of C. elegans-based assays. Commercializing SydLab One as ready to use the released product will make this solution accessible to a much larger customers base and it will propel the growth of Nagi Bioscience”, explains Chris Radloff, PhD, board member of Nagi Bioscience and 25+ years expert on laboratory automation.

(Press release)